A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses

Vaccine

Volumn 32, Issue 21, 2014, Pages 2406-2412

  Cai, Yicun ^a   Ku, Zhiqiang ^a   Liu, Qingwei ^a   Leng, Qibin ^a   Huang, Zhong ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

Author keywords

Bivalent vaccine; Coxsackievirus A16; Enterovirus 71; Neutralizing antibody; Passive protection

Indexed keywords

ANTIBODY; INACTIVATED VIRUS VACCINE; MONOVALENT INACTIVATED COXSACKIEVIRUS A16 VACCINE; MONOVALENT INACTIVATED ENTEROVIRUS 71 VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS INFECTION; DRUG EFFICACY; ENTEROVIRUS INFECTION; FEMALE; IMMUNOGENICITY; IN VIVO STUDY; INFECTION PREVENTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROVOCATION TEST; VIRUS IMMUNITY; VIRUS NEUTRALIZATION;

BIVALENT VACCINE; COXSACKIEVIRUS A16; ENTEROVIRUS 71; NEUTRALIZING ANTIBODY; PASSIVE PROTECTION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS; ENTEROVIRUS A, HUMAN; FEMALE; HAND, FOOT AND MOUTH DISEASE; IMMUNIZATION, PASSIVE; MICE; MICE, INBRED ICR; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VACCINES, COMBINED; VERO CELLS; VIRAL VACCINES;

EID: 84898437031     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.03.012     Document Type: Article

References (49)

1. Wong S.S., Yip C.C., Lau S.K., Yuen K.Y. Human enterovirus 71 and hand, foot and mouth disease. Epidemiol Infect 2010, 138(August (8)):1071-1089.
2. Lee M.S., Tseng F.C., Wang J.R., Chi C.Y., Chong P., Su I.J. Challenges to licensure of enterovirus 71 vaccines. PLoS Negl Trop Dis 2012, 6(8):e1737.
3. Ang L.W., Koh B.K., Chan K.P., Chua L.T., James L., Goh K.T. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001-2007. Ann Acad Med Singapore 2009, 38(February (2)):106-112.
4. Solomon T., Lewthwaite P., Perera D., Cardosa M.J., McMinn P., Ooi M.H. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010, 10(November (11)):778-790.
5. Mao Q., Wang Y., Yao X., Bian L., Wu X., Xu M., et al. Coxsackievirus A16: Epidemiology, diagnosis, and vaccine. Hum Vaccin Immunother 2013, 10.(November (2)).
6. Chang L.Y., Lin T.Y., Huang Y.C., Tsao K.C., Shih S.R., Kuo M.L., et al. Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J 1999, 18(December (12)):1092-1096.
7. Hosoya M., Kawasaki Y., Sato M., Honzumi K., Hayashi A., Hiroshima T., et al. Genetic diversity of coxsackievirus A16 associated with hand, foot, and mouth disease epidemics in Japan from 1983 to 2003. J Clin Microbiol 2007, 45(January (1)):112-120.
8. Iwai M., Masaki A., Hasegawa S., Obara M., Horimoto E., Nakamura K., et al. Genetic changes of coxsackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in Toyama, Japan between 1981 and 2007. Jpn J Infect Dis 2009, 62(July (4)):254-259.
9. McMinn P.C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 2002, 26(March (1)):91-107.
10. Liu F., Liu Q., Cai Y., Leng Q., Huang Z. Construction and characterization of an infectious clone of coxsackievirus A16. Virol J 2011, 8:534.
11. Chong P., Guo M.S., Lin F.H., Hsiao K.N., Weng S.Y., Chou A.H., et al. Immunological and biochemical characterization of coxsackie virus A16 viral particles. PLoS ONE 2012, 7(11):e49973.
12. Liu C.C., Guo M.S., Lin F.H., Hsiao K.N., Chang K.H., Chou A.H., et al. Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS ONE 2011, 6(5):e20005.
13. Lee T.C., Guo H.R., Su H.J., Yang Y.C., Chang H.L., Chen K.T. Diseases caused by enterovirus 71 infection. Pediatr Infect Dis J 2009, 28(October (10)):904-910.
14. Wright H.T., Landing B.H., Lennette E.H., Mc A.R. Fatal infection in an infant associated with Coxsackie virus group A, type 16. N Engl J Med 1963, 268(May (9)):1041-1044.
15. Goldberg M.F., McAdams A.J. Myocarditis possibly due to Coxsackie group A, type 16, virus. J Pediatr 1963, May (62):762-765.
16. Wang C.Y., Lu F.L., Wu M.H., Lee C.Y., Huang L.M. Fatal coxsackievirus A16 infection. Pediatr Infect Dis J 2004, 23(March (3)):275-276.
17. Legay F., Leveque N., Gacouin A., Tattevin P., Bouet J., Thomas R., et al. Fatal coxsackievirus A-16 pneumonitis in adult. Emerg Infect Dis 2007, 13(July (7)):1084-1086.
18. Goto K., Sanefuji M., Kusuhara K., Nishimura Y., Shimizu H., Kira R., et al. Rhombencephalitis and coxsackievirus A16. Emerg Infect Dis 2009, 15(October (10)):1689-1691.
19. Xu W., Liu C.F., Yan L., Li J.J., Wang L.J., Qi Y., et al. Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol J 2012, 9(1):8.
20. Pan H., Zhu Y.F., Qi X., Zhang Y.J., Li L., Deng F., et al. Analysis on the epidemiological and genetic characteristics of enterovirus type 71 and Coxsackie A16 virus infection in Jiangsu, China. Zhonghua Liu Xing Bing Xue Za Zhi 2009, 30(April (4)):339-343.
21. Zhang H.M., Li C.R., Liu Y.J., Liu W.L., Fu D., Xu L.M., et al. To investigate pathogen of hand, foot and mouth disease in Shenzhen in 2008. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2009, 23(October (5)):334-336.
22. Zhang W., Wang Y.G., Yang Z.H., Pang B.D., Wu H., Yang Q.Z., et al. Severe hand-foot-and-mouth disease caused by mixed infection of enterovirus 71 and coxsackie A16: reports of 6 cases. Chinese General Practice 2011, 29:3341-3343.
23. Yip C.C., Lau S.K., Zhou B., Zhang M.X., Tsoi H.W., Chan K.H., et al. Emergence of enterovirus 71 double-recombinant strains belonging to a novel genotype D originating from southern China: first evidence for combination of intratypic and intertypic recombination events in EV71. Arch Virol 2010, 155(September (9)):1413-1424.
24. Zhang Y., Zhu Z., Yang W., Ren J., Tan X., Wang Y., et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J 2010, 7:94.
25. Heinsbroek E., Ruitenberg E.J. The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox. Vaccine 2010, 28(May (22)):3778-3783.
26. Xu J., Qian Y., Wang S., Serrano J.M., Li W., Huang Z., et al. EV71: an emerging infectious disease vaccine target in the Far East?. Vaccine 2010, 28(April (20)):3516-3521.
27. Lee M.S., Chang L.Y. Development of enterovirus 71 vaccines. Expert Rev Vaccines 2010, 9(February (2)):149-156.
28. Liang Z., Mao Q., Gao F., Wang J. Progress on the research and development of human enterovirus 71 (EV71) vaccines. Front Med 2013, 7(March (1)):111-121.
29. Zhu F.C., Meng F.Y., Li J.X., Li X.L., Mao Q.Y., Tao H., et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013, 381(June (9882)):2024-2032.
30. Cai Y., Liu Q., Huang X., Li D., Ku Z., Zhang Y., et al. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine 2013, 31(April (18)):2215-2221.
31. Mao Q., Wang Y., Gao R., Shao J., Yao X., Lang S., et al. A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol 2012, 86(November (22)):11967-11976.
32. Liu Q., Ku Z., Cai Y., Sun B., Leng Q., Huang Z. Detection, characterization and quantitation of coxsackievirus A16 using polyclonal antibodies against recombinant capsid subunit proteins. J Virol Methods 2011, 173(April (1)):115-120.
33. Liu Q., Huang X., Ku Z., Wang T., Liu F., Cai Y., et al. Characterization of enterovirus 71 capsids using subunit protein-specific polyclonal antibodies. J Virol Methods 2013, 187(January (1)):127-131.
34. Ku Z., Shi J., Liu Q., Huang Z. Development of murine monoclonal antibodies with potent neutralization effects on enterovirus 71. J Virol Methods 2012, 186(December (1-2)):193-197.
35. Yang C., Deng C., Wan J., Zhu L., Leng Q. Neutralizing antibody response in the patients with hand, foot and mouth disease to enterovirus 71 and its clinical implications. Virol J 2011, 8:306.
36. Reed L.J.M.H. A simple method of estimating 50 percent endpoints. Am J Hyg 1938, 27:493-499.
37. Ku Z., Ye X., Huang X., Cai Y., Liu Q., Li Y., et al. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLoS ONE 2013, 8(2):e57601.
38. Yang F., Zhang T., Hu Y., Wang X., Du J., Li Y., et al. Survey of enterovirus infections from hand, foot and mouth disease outbreak in China, 2009. Virol J 2011, 8:508.
39. Berger R., Just M., Gluck R. Interference between strains in live virus vaccines. I. Combined vaccination with measles, mumps and rubella vaccine. J Biol Stand 1988, 16(October (4)):269-273.
40. Berger R., Just M. Interference between strains in live virus vaccines. II. Combined vaccination with varicella and measles-mumps-rubella vaccine. J Biol Stand 1988, 16(October (4)):275-279.
41. Payne A.M. Oral immunization against poliomyelitis. Bull World Health Organ 1960, 23(6):695-703.
42. Patriarca P.A., Wright P.F., John T.J. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991, 13(September-October (5)):926-939.
43. Guy B., Barban V., Mantel N., Aguirre M., Gulia S., Pontvianne J., et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009, 80(February (2)):302-311.
44. Anderson K.B., Gibbons R.V., Edelman R., Eckels K.H., Putnak R.J., Innis B.L., et al. Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate. J Infect Dis 2011, 204(August (3)):442-450.
45. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002, 66(March (3)):264-272.
46. Sun W., Edelman R., Kanesa-Thasan N., Eckels K.H., Putnak J.R., King A.D., et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003, 69(December (6 Suppl.)):24-31.
47. Kitchener S., Nissen M., Nasveld P., Forrat R., Yoksan S., Lang J., et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 2006, 24(February (9)):1238-1241.
48. Takada A., Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 2003, 13(November-December (6)):387-398.
49. Huisman W., Martina B.E., Rimmelzwaan G.F., Gruters R.A., Osterhaus A.D. Vaccine-induced enhancement of viral infections. Vaccine 2009, 27(January (4)):505-512.